Statistiche di base
| CIK | 1626644 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Odyssey Health, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 18, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission F |
|
| May 26, 2026 |
Amendment #12 to Convertible Promissory Note Exhibit 10.1 Amendment #12 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of April 30, 2026 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Health Inc, formerly Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into th |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 6, 2026 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 11, 2026 |
24 Quaker Lane, Unit J, Warwick, RI 02886 Exhibit 10.1 NeuRX Health, Inc. Tel: 401-225-6000 May 6, 2026 Revocation of Planned Sub-License Agreement RE: NeuRX Health Inc. and Odyssey Health Inc. Dear Mr. Redmond: In the last few day, we were made aware of the fact that our licensing and royalty agreement(s) with Davion Healthcare Plc (“Davion”), related to their BreastCheck product, which includes global licenses for both the manufacturing |
|
| April 24, 2026 |
AMENDMENT NO. 1 TO THE MASTER TECHNOLOGY SUB-LICENSE AGREEMENT Exhibit 10.2 AMENDMENT NO. 1 TO THE MASTER TECHNOLOGY SUB-LICENSE AGREEMENT This AMENDMENT (this “Amendment”) is entered into as of April 21, 2026, the “Effective Date”), and made effective as of the Effective Date, by and between Odyssey Health, Inc., its wholly owned subsidiary, Odyssey Medical Devices, Inc., a Nevada corporation, (the “Company” “Licensee”), and NeuRX Health, Inc. a Wyoming corp |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 21, 2026 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| April 24, 2026 |
Exhibit 99.1 Odyssey Health, Inc. Secures Exclusive Global Distribution Rights for BreastCheck™ to Drive Recurring Revenue Growth Agreement Positions Company for Near-Term Revenue and Commercial Launch LAS VEGAS, NV, April 22, 2026 (GLOBE NEWSWIRE) — Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on life-saving technologies, today announced the closing of a definitive sub-lic |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0 |
|
| February 3, 2026 |
Amendment #12 to Promissory Note Exhibit 10.1 Amendment #12 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of January 30, 2026 (the “Effective Date”), and binding on the undersigned parties as of that date. Odyssey Health, Inc. formerly Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory |
|
| February 3, 2026 |
Exhibit 10.3 Effective date January 30, 2026: Amendment No. 5 – The definition of the maturity date (“Maturity Date”) will be changed to the following: The Maturity Date shall now be January 31, 2027. All other terms and conditions of the Convertible Promissory Note and Amendments number one (1), two (2), three (3), and four (4) remain the same. IN WITNESS WHEREOF, the undersigned has executed thi |
|
| February 3, 2026 |
Amendment #11 to Convertible Promissory Note Exhibit 10.2 Amendment #11 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of January 30, 2026 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Health Inc, formerly Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 30, 2026 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 3, 2026 |
Amendment No. 2 to Promissory Note Exhibit 10.4 Amendment No. 2 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of January 31, 2026 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Health, Inc. (“BORROWER”) and Peter J. D’Arruda (“LENDER”) entered into that certain Promissory Note (the “Note”) dated August |
|
| December 30, 2025 |
18,000,000 Shares Common Stock Odyssey Health Incorporated S-1 Filed Pursuant to Rule 424(b)(3) Registration No. 333-292311 PROSPECTUS 18,000,000 Shares Common Stock This prospectus relates to the resale of up to Eighteen Million (18,000,000) shares of our common stock by Mast Hill Fund, L.P. (“Mast Hill Fund”) upon the conversion of promissory notes and warrants being registered under this Form S-1. The shares of our Common St |
|
| December 19, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Odyssey Health, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0 |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025. As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Odyssey Health Incorporated (Exact name of Registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation or Organization) 3841 (Primary |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 00 |
|
| November 19, 2025 |
Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 13, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 19, 2025 |
Exhibit 99.1 Odyssey Health, Inc. Secures Multi-Million-Dollar, Nine-Year Service Contract and Financing Facility for Up to $25 Million Service agreement and financing facility supports strategic growth and commercialization initiatives LAS VEGAS, NV – November 19, 2025 (GLOBE NEWSWIRE) – Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on developing and commercializing life-sa |
|
| November 19, 2025 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 13, 2025, by and between ODYSSEY HEALTH, INC., a Nevada corporation, with headquarters located at 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV 89102 (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership, with its address at 150 Grossman Drive, Suite |
|
| November 19, 2025 |
Exhibit 10.1 Maintenance Agreement This maintenance agreement (this “Agreement”) is made and entered into as of November 13, 2025 (the “Effective Date”), by and between Mast Hill Fund, L.P., a Delaware limited partnership (the “MHF”) and Odyssey Health, Inc., a Nevada corporation (“Service Provider”), regarding the facility identified on Schedule III attached hereto (the “Facility”). MHF and Servi |
|
| November 19, 2025 |
Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| November 19, 2025 |
COMMON STOCK PURCHASE WARRANT ODYSSEY HEALTH, INC. Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-56196 ODYSSEY HEALT |
|
| October 29, 2025 |
Amendment #3 to Promissory Note Exhibit 10.17 Amendment #3 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of September 30, 2022 (the “Effective Date”), and binding on the undersigned parties as of that date. Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory Note (the “Note”) dated Dec |
|
| October 29, 2025 |
Exhibit 10.66 PROMISSORY NOTE THIS PROMISSORY NOTE (the “Note”) is made as of the 14thst day of August 2024, by and between Odyssey Health, Inc., Nevada corporation, (hereinafter known as “BORROWER”) and Peter J. D’Arruda, an individual (hereinafter known as “LENDER”), whose address is 124 Poppleford Place, Cary, NC 27518. BORROWER and LENDER shall collectively be known herein as “the Parties”. In |
|
| October 29, 2025 |
Exhibit 10.67 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRA |
|
| October 29, 2025 |
ODYSSEY HEALTH, INC. POLICY ON INSIDER TRADING Exhibit 19.1 ODYSSEY HEALTH, INC. POLICY ON INSIDER TRADING All Employees (Including temporary employees) consultants, independent contractors, officers and members of the Board of Directors of Odyssey Health, Inc. and any subsidiaries (collectively, the “Company”). Introduction You may learn confidential and sensitive information concerning the Company, its vendors, suppliers, distributors, or ot |
|
| October 29, 2025 |
Amendment #8 to Convertible Promissory Note Exhibit 10.37 Amendment #8 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of June 30, 2024 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Health Inc, formerly Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into tha |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 14, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 17, 2025 |
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace Exhibit 99.1 Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) - Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announce |
|
| October 17, 2025 |
Exhibit 10.1 MASTER TECHNOLOGY SUB-LICENSE AGREEMENT by and among ODYSSEY HEALTH, INC., AND ODYSSEY MEDICAL DEVICES, INC. (A WHOLLY OWNED SUBSIDIARY OF ODYSSEY HEALTH, INC.) AND NEURX HEALTH, INC., This Technology and Sub-license Agreement (the “Agreement”) dated as of October 17, 2025 (the “Effective Date”), by and between NeuRX Health Inc., a Rhode Island corporation, whose address is 24 Quaker |
|
| October 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 9, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| October 10, 2025 |
AMENDMENT #6 TO THE PROMISSORY NOTE ISSUED ON DECEMBER 13, 2022 Exhibit 10.1 AMENDMENT #6 TO THE PROMISSORY NOTE ISSUED ON DECEMBER 13, 2022 THIS AMENDMENT #6 to the Note (as defined below) (the “Amendment”) is entered into as of October 9, 2025 (the “Effective Date”), and made effective as of the Effective Date, by and between ODYSSEY HEALTH, INC., a Nevada corporation (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership (the “Holder”) (c |
|
| October 8, 2025 |
Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRAN |
|
| October 8, 2025 |
Exhibit 10.1 PROMISSORY NOTE THIS PROMISSORY NOTE (the “Note”) is made as of the 1st day of October 2025, by and between Odyssey Health, Inc., Nevada corporation, (hereinafter known as “BORROWER”) and Peter J. D’Arruda, an individual (hereinafter known as “LENDER”), whose address is 124 Poppleford Place, Cary, NC 27518. BORROWER and LENDER shall collectively be known herein as “the Parties”. In de |
|
| October 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 3, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 18, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission F |
|
| September 22, 2025 |
Amendment #10 to Convertible Promissory Note Exhibit 10.1 Amendment #10 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of July 31, 2025 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Health Inc, formerly Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into tha |
|
| August 29, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 27, 2025, by and between ODYSSEY HEALTH, INC., a Nevada corporation, with headquarters located at 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV 89102 (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership, with its address at 150 Grossman Drive, Suite 2 |
|
| August 29, 2025 |
Exhibit 10. 2 THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGIST |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 27, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| August 29, 2025 |
COMMON STOCK PURCHASE WARRANT ODYSSEY HEALTH, INC. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| August 20, 2025 |
20,000,000 Shares Odyssey Health Incorporated Common Stock S-1 PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-289233 20,000,000 Shares Odyssey Health Incorporated Common Stock This prospectus relates to the sale of up to Twenty Million (20,000,000) shares of our common stock by, Mast Hill Fund, L.P. (“Mast Hill Fund”). The shares of our common stock to which this prospectus relates have been or may be issued by us to Mast Hill Fund pursu |
|
| August 15, 2025 |
REQUEST FOR ACCELERATION OF EFFECTIVENESS August 15, 2025 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 14, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2025 |
Exhibit 10.1 Amendment No. 1 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of August 14, 2025 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Health, Inc. (“BORROWER”) and Peter J. D’Arruda (“LENDER”) entered into that certain Promissory Note (the “Note”) dated August |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025. As filed with the Securities and Exchange Commission on August 15, 2025. Registration No. 333- 333-289233 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1/A REGISTRATION STATEMENT Under The Securities Act of 1933 Odyssey Health Incorporated (Exact name of Registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025. As filed with the Securities and Exchange Commission on August 15, 2025. Registration No. 333-289233 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT Under The Securities Act of 1933 Odyssey Health Incorporated (Exact name of Registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation or Or |
|
| August 13, 2025 |
Exhibit 10.1 Effective date July 31, 2025: Amendment No. 4 – The definition of the maturity date (“Maturity Date”) will be changed to the following: The Maturity Date shall now be January 31, 2026. All other terms and conditions of the Convertible Promissory Note and Amendments number one (1) two (2) and three (3) remain the same. IN WITNESS WHEREOF, the undersigned has executed this Secured Conve |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 7, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2025 |
August 11, 2025 Joseph Michael Redmond Chief Executive Officer Odyssey Health, Inc. |
|
| August 5, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Odyssey Health, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0 |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 4, 2025. As filed with the Securities and Exchange Commission on August 4, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Odyssey Health Incorporated (Exact name of Registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation or Organization) 3841 (Primary St |
|
| August 4, 2025 |
Exhibit 10.1 Amendment #11 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of July 31, 2025 (the “Effective Date”), and binding on the undersigned parties as of that date. Odyssey Health, Inc. formerly Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory No |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 31, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 4, 2025 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT This equity purchase agreement (this "Agreement") is made and entered into as of August 4, 2025 (this "Agreement"), by and between Odyssey Health, Inc., a Nevada corporation (the "Company"), and Mast Hill Fund, L.P., a Delaware limited partnership (the "Investor", and collectively with the Company, the “Parties”). WHEREAS, the Parties desire that, upon the te |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2025 Date of Report (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of July 29, 2025, by and between ODYSSEY HEALTH, INC., a Nevada corporation (the "Company"), and MAST HILL FUND, L.P., a Delaware limited partnership (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective mean |
|
| July 11, 2025 |
Amendment No. 5 to the Promissory Note with Mast Hill, L.P. Exhibit 10.1 AMENDMENT #5 TO THE PROMISSORY NOTE ISSUED ON DECEMBER 13, 2022 THIS AMENDMENT #5 to the Note (as defined below) (the “Amendment”) is entered into as of July 11, 2025 (the “Effective Date”), and made effective as of the Effective Date, by and between ODYSSEY HEALTH, INC., a Nevada corporation (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership (the “Holder”) (col |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 11, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 13, 2025 |
Exhibit 10.1 AMENDMENT #4 TO THE PROMISSORY NOTE ISSUED ON DECEMBER 13, 2022 THIS AMENDMENT #4 to the Note (as defined below) (the “Amendment”) is entered into as of June 10, 2025 (the “Effective Date”), and made effective as of the Effective Date, by and between ODYSSEY HEALTH, INC., a Nevada corporation (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership (the “Holder”) (col |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 23, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0 |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 13, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 19, 2025 |
Amendment No. 9 to Convertible Promissory Note with LGH Investments, LLC Exhibit 10.2 Amendment #9 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of December 31, 2024 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Health Inc, formerly Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into |
|
| February 19, 2025 |
Amendment No. 3 to Promissory Note with accredited investor Jonathan Lutz, dated February 13, 2024 Exhibit 10.1 Amendment No. 3 to Promissory Note Effective date February 13, 2025: Amendment No. 3 – The definition of the maturity date (“Maturity Date”) will be changed to the following: The Maturity Date shall now be July 31, 2025. All other terms and conditions of the Convertible Promissory Note and Amendment number one (1) and amendment two (2) remain the same. IN WITNESS WHEREOF, the undersig |
|
| February 6, 2025 |
Form of Amendment No. 10 to Promissory Note Exhibit 10.1 Amendment #10 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of January 31, 2025 (the “Effective Date”), and binding on the undersigned parties as of that date. Odyssey Health, Inc. formerly Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 31, 2025 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 0 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 000-56196 ODYSSEY HEAL |
|
| November 13, 2024 |
Exhibit 10.60 THIS SECURED CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS SECURED CONVERTIBLE NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATIO |
|
| November 13, 2024 |
Exhibit 10.61 Effective date August 13, 2024: Amendment No. 2 – The definition of the maturity date (“Maturity Date”) will be changed to the following: The Maturity Date shall now be twelve months from the Effective Date of the Convertible Promissory Note between Lendor and Borrower dated February 13, 2024. All other terms and conditions of the Convertible Promissory Note and Amendment number one |
|
| November 13, 2024 |
Pledge Agreement dated October 29, 2024, with Mast Hill Fund, L.P. Exhibit 10.63 PLEDGE AGREEMENT This PLEDGE AGREEMENT (this “Agreement”), dated as of October 29, 2024 (the “Effective Date”), made by and between Odyssey Health, Inc., a Nevada corporation (together with its successors and assigns, the “Pledgor”) and Mast Hill Fund, L.P., a Delaware limited partnership (together with its successors and assigns, the “Pledgees”). WHEREAS: A. Pledgor and Pledgees are |
|
| November 13, 2024 |
Exhibit 10.32 Amendment #9 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of July 31, 2024 (the “Effective Date”), and binding on the undersigned parties as of that date. Odyssey Health, Inc. formerly Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory No |
|
| November 13, 2024 |
Exhibit 10.62 AMENDMENT #3 TO THE PROMISSORY NOTE ISSUED ON DECEMBER 13, 2022 THIS AMENDMENT #3 to the Note (as defined below) (the “Amendment”) is entered into as of October 29, 2024, and made effective as of September 13, 2024, by and between ODYSSEY HEALTH, INC., a Nevada corporation (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership (the “Holder”) (collectively the “Part |
|
| November 4, 2024 |
ODYY / Odyssey Health, Inc. / Lutz Jonathan D - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Odyssey Health, Inc. (Name of Issuer) ODYY - Common Stock, par value $0.001 (Title of Class of Securities) 67612C102 (CUSIP Number) October 29, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: July 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 22, 2024 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| August 23, 2024 |
Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRAN |
|
| August 23, 2024 |
Exhibit 10.1 PROMISSORY NOTE THIS PROMISSORY NOTE (the “Note”) is made as of the 14thst day of August 2024, by and between Odyssey Health, Inc., Nevada corporation, (hereinafter known as “BORROWER”) and Peter J. D’Arruda, an individual (hereinafter known as “LENDER”), whose address is ****. BORROWER and LENDER shall collectively be known herein as “the Parties”. In determining the rights and dutie |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 00 |
|
| March 22, 2024 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. |
|
| March 22, 2024 |
Promissory Note with accredited investor Jonathan Lutz, dated February 13, 2024 Exhibit 10.4 THIS SECURED CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS SECURED CONVERTIBLE NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| March 22, 2024 |
Exhibit 10.3 Amendment #8 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of January 31, 2024 (the “Effective Date”), and binding on the undersigned parties as of that date. Odyssey Health, Inc. formerly Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: January 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| February 12, 2024 |
OGEN / Oragenics, Inc. / Odyssey Health, Inc. - SCHEDULE 13D Activist Investment SC 13D 1 odysseysch13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Oragenics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) Common Stock 684023302 (CUSIP Number) Odyssey Health, Inc. Joseph M. Redmond 2300 West Sahara Avenue Suite 800 |
|
| January 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Odyssey Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 p |
|
| January 5, 2024 |
Amendment No. 7 to Convertible Promissory Note with LGH Investments dated April 5, 2021 Exhibit 10.1 Amendment #7 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of December 30, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into that certain Convertible Prom |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 30, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 47-1022125 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 230 |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 47-1022125 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2300 West Sahara Avenue, Suite 800 - #4012 Las Vegas, NV 89102 (Addre |
|
| January 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Odyssey Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 p |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 47-1022125 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2300 West Sahara Avenue, Suite 800 - #4012 Las Vegas, NV 89102 (Addre |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 28, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission F |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 0 |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 12, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 13, 2023 |
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc. Exhibit 99.1 Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc. LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. (OTCOB:ODYY), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the sale of its neurological drug |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 7, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 000- |
|
| November 2, 2023 |
Exhibit 10.1 Amendment #7 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between the Company and Holder (each as defined below), effective as of November 1, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory Note (the “Note”) dated December , |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 1, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 30, 2023 |
Promissory Note with accredited investor Jonathan Lutz, dated September 21, 2022 Exhibit 10.49 Exhibit 10.49 PROMISSORY NOTE THIS PROMISSORY NOTE (the “Note”) is made as of the 21st day September 2022, by and between Odyssey Health, Inc., a Nevada corporation, (hereinafter known as “BORROWER”) and Jonathon Lutz, an individual (hereinafter known as “LENDER”), whose address is 16357 E 18th Place Aurora, CO 80011. BORROWER and LENDER shall collectively be known herein as “the Par |
|
| October 30, 2023 |
Convertible Promissory Note dated August 29, 2021 with Tysadco Partners, LLC Exhibit 10.38 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 29, 2021 is entered into by and between Odyssey Group Intl Inc., a Nevada corporation, (the “Company”), and Tysadco Partners (the “Buyer”). A.The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded b |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 000-56196 ODYSSEY HEAL |
|
| October 30, 2023 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| October 19, 2023 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 5, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| October 5, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 4, 2023 (Date of earliest event reported) ODYSSEY HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| October 5, 2023 |
Exhibit 99.1 Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate Gains Nasal Delivery Technologies and Expands Product Pipeline TAMPA, Fla. and LAS VEGAS, Nev. (October 5, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY) (“Odyssey”) announce the signing of a definitive agr |
|
| October 5, 2023 |
Asset Purchase Agreement Closing with Oragenics, Inc., dated December 28, 2023 Exhibit 2.1 ASSET Purchase Agreement by and among Oragenics Corporation and Odyssey Health, Inc. f/k/a Odyssey Group International, INC. And Joseph Michael Redmond And Christine Farrell October 4, 2023 TABLE OF CONTENTS Page Article 1 SALE OF ASSETS 1 Section 1.1. Purchase and Sale of Assets 1 Section 1.2. Excluded Assets 3 Section 1.3. Assumed Liabilities 4 Section 1.4. Excluded Liabilities 4 Sec |
|
| August 18, 2023 |
EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| August 18, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 18, 2023 |
EXHIBIT 10.2 THIS SECURED CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS SECURED CONVERTIBLE NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| August 18, 2023 |
EXHIBIT 10.1 NOTE PURCHASE AGREEMENT NEITHER THE CONVERTIBLE SUBORDINATED NOTE (THE “NOTE”) NOR THE SHARES OF COMMON STOCK INTO WHICH THE PRINCIPAL AND INTEREST SHALL BE CONVERTED THEREUNDER (THE “CONVERSION SHARES”), BOTH OF WHICH ARE REFERRED TO HEREIN, HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”) OR UNDER ANY STATE SECURITIES (“BLUE SKY”) LAWS. THE SECURITIE |
|
| July 28, 2023 |
ODYY / Odyssey Group Intl Inc / Lutz Jonathan D - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Odyssey Health, Inc. (Name of Issuer) ODYY - Common Stock, par value $0.001 (Title of Class of Securities) 67612C102 (CUSIP Number) July 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| July 7, 2023 |
Exhibit 10.2 Amendment #6 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of July 6, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into that certain Convertible Promissor |
|
| July 7, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 7, 2023 |
Exhibit 10.1 Amendment #6 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of June 30, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory Note (the “Note”) dated December 21, 2021 |
|
| June 28, 2023 |
Speranza Therapeutics announces letter of intent to merge with public company, Odyssey Health Inc. Exhibit 99.1 Speranza Therapeutics announces letter of intent to merge with public company, Odyssey Health Inc. BOCA RATON, Fla. (PRWEB) June 28, 2023 Speranza Therapeutics, Inc. (“Speranza”), a medical technology company dedicated to providing better patient outcomes by addressing large, underserved markets, and Odyssey Health Inc (OTC: ODYY) or (“Odyssey”), a publicly traded medical device compa |
|
| June 28, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 00 |
|
| June 14, 2023 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| June 14, 2023 |
Exhibit 10.4 AMENDMENT #1 TO THE PROMISSORY NOTE ISSUED ON DECEMBER 13, 2022 THIS AMENDMENT #1 to the Note (as defined below) (the “Amendment”) is entered into as of June 13, 2023 (the “Effective Date”), by and between ODYSSEY HEALTH, INC., a Nevada corporation (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership (the “Holder”) (collectively the “Parties”). BACKGROUND A. The C |
|
| June 14, 2023 |
Exhibit 10.3 Amendment No 2 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of June 9, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Health, Inc. (“BORROWER”) and Jonathan Lutz (“LENDER”) entered into that certain Promissory Note (the “Note”) dated September 21, 2 |
|
| April 4, 2023 |
Exhibit 10.2 Amendment #5 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of March 31, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entered into that certain Promissory Note (the “Note”) dated December 21, 202 |
|
| April 4, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 4, 2023 |
Amendment No. 5 to the Convertible Promissory Note Exhibit 10.1 Amendment #5 to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of March 31, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (“Company”) and LGH Investments, LLC (“Holder”) entered into that certain Convertible Promiss |
|
| March 17, 2023 |
Exhibit 10.5 SECOND AMENDMENT AND ASSIGNMENT TO CONVERTIBLE PROMISSORY NOTE THIS SECOND AMENDMENT AND ASSIGNMENT TO CONVERTIBLE PROMISSORY NOTE (the "Second Amendment") is made effective as of March 14, 2023, by and between Odyssey Group International, Inc. (dba Odyssey Health, Inc.) (the “Borrower”), and Tysadco Partners, LLC (together with its successors and permitted assigns, the “Lender”). The |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. |
|
| March 17, 2023 |
Exhibit 10.4 Amendment #2 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of January 31, 2023 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Health, Inc. (“BORROWER”) and Jonathan Lutz (“LENDER”) entered into that certain Promissory Note (the “Note”) dated September 21, |
|
| January 13, 2023 |
Submission of Matters to a Vote of Security Holders U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission F |
|
| January 6, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 3, 2023 |
Exhibit 10.3 Amendment #1 to Promissory Note This AMENDMENT (this ?AMENDMENT?) is entered into by and between Company and Holder (each as defined below), effective as of December 30, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. Odyssey Health, Inc. (?BORROWER?) and Jonathan Lutz (?LENDER?) entered into that certain Promissory Note (the ?Note?) dated September 21 |
|
| January 3, 2023 |
Exhibit 10.1 Amendment #4 to Convertible Promissory Note This AMENDMENT (this ?Amendment?) is entered into by and between Company and Holder (each as defined below), effective as of December 29, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (?Company?) and LGH Investments, LLC (?Holder?) entered into that certain Convertible Prom |
|
| January 3, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| January 3, 2023 |
EX-10.2 3 odysseyex1002.htm FORM OF AMENDMENT #4 TO PROMISSORY NOTE Exhibit 10.2 Amendment #4 to Promissory Note This AMENDMENT (this “AMENDMENT”) is entered into by and between Company and Holder (each as defined below), effective as of December 30, 2022 (the “Effective Date”), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (“BORROWER”) and (“LENDER”) entere |
|
| December 14, 2022 |
Promissory Note issued to Mast Hill Fund, L.P. on December 13, 2022 Exhibit 10.5 THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTE |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 0 |
|
| December 14, 2022 |
EX-10.4 3 odyyex1004.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 13, 2022, by and between ODYSSEY HEALTH, INC., a Nevada corporation, with headquarters located at 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV 89102 (the “Company”), and MAST HILL FUND, L.P., a Delaware limited par |
|
| December 14, 2022 |
Second Warrant issued to Mast Hill Fund, L.P. on December 13, 2022 Exhibit 10.7 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| December 14, 2022 |
First Warrant issued to Mast Hill Fund, L.P. on December 13, 2022 Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| November 29, 2022 |
DEF 14A 1 odysseydef14a.htm PROXY STATEMENT Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| November 25, 2022 |
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) - Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a Company update and recap of its |
|
| November 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| November 23, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| November 23, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| November 23, 2022 |
Exhibit 10.1 OPTION AGREEMENT by and among ODYSSEY HEALTH INC., AND PREVACUS, INC. This AGREEMENT FOR AN OPTION TO PURCHASE INTELLECTUAL PROPERTY, dated as of November 22, 2022 (this ?Agreement?), by and among Prevacus Inc. a Delaware Corporation (?Prevacus?), and, Odyssey Health Inc., a Nevada corporation (?Odyssey?), whose address is 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas NV 89102 |
|
| November 18, 2022 |
PRE 14A 1 odysseypre14a.htm PRELIMINARY PROXY STATEMENT Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the C |
|
| November 4, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into by and between Odyssey Pharmaceuticals a wholly owned subsidiary of Odyssey Health Inc (the ?Company?) a Nevada Corporation and Erik Emerson (the ?Executive?) whose address is . WHEREAS, the Company desires to employ the Executive as its Chief Commercial Officer and the Executive desires to serve in such |
|
| November 4, 2022 |
Exhibit 99.1 Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) - Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, is pleased to announce its continued com |
|
| November 4, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into by and between Odyssey NeuroPharma, Inc., a wholly owned subsidiary of Odyssey Health, Inc., (the ?Company?) a Nevada Corporation and Greg Gironda (the ?Executive?) whose address is. WHEREAS, the Company desires to employ the Executive as its Chief Operating Officer and the Executive desires to serve in s |
|
| November 4, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission F |
|
| November 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission F |
|
| November 1, 2022 |
Exhibit 99.1 Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device Las Vegas, NV, November 1, 2022 ? McapMediaWire ?Odyssey Health, Inc. (OTC: ODYY) (the "Company" or "Odyssey"), announced that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (?Nasal Device |
|
| October 31, 2022 |
Exhibit 10.10 NEITHER ThIS PURCHASE WARRANT NOR THE securities represented by this PURChASE warrant have been registered under the Securities Act of 1933, as amended, or applicable state law. Neither thIS PURCHASE WARRANT NOT THE UNDERLYING securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant to an effective registration statement under the Sec |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 333-200785 ODYSSEY HEA |
|
| October 3, 2022 |
Exhibit 10.1 Amendment #3 to Convertible Promissory Note This AMENDMENT (this ?Amendment?) is entered into by and between Company and Holder (each as defined below), effective as of September 29, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (?Company?) and LGH Investments, LLC (?Holder?) entered into that certain Convertible Pro |
|
| October 3, 2022 |
Form of Amendment No. 3 to Promissory Note Exhibit 10.2 Amendment #3 to Promissory Note This AMENDMENT (this ?AMENDMENT?) is entered into by and between Company and Holder (each as defined below), effective as of September 30, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (?BORROWER?) and LENDER (?LENDER?) entered into that certain Promissory Note (the ?Note?) dated Decem |
|
| October 3, 2022 |
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program Exhibit 99.1 Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International, Inc., (the ?Company? ?Odyssey?) a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board. The sports advisory members have |
|
| October 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| September 30, 2022 |
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) - Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces the completion of all cohorts |
|
| September 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| September 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2022 |
EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial Las Vegas, NV, Aug. 18, 2022 (GLOBE NEWSWIRE) - Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of |
|
| August 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 9, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-266422 PROSPECTUS 6,696,313 Shares Common Stock This prospectus relates to the resale of shares of our Common stock, par value $0.001 per share (the ?Common Stock?), of an aggregate of 6,696,313 Common Stock Shares sold pursuant to the private investment in public entity dated July 29, 2022, of 4,058,372 Units consisting of on |
|
| August 4, 2022 |
REQUEST FOR ACCELERATION OF EFFECTIVENESS CORRESP 1 filename1.htm August 4, 2022 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Odyssey Health, Inc. Registration Statement on Form S-1 Filed July 29, 2022 File No. 333-266422 REQUEST FOR ACCELERATION OF EFFECTIVENESS Dear Mr. Gorsky, Pursuant to Rule 461 under the Securities Act |
|
| August 3, 2022 |
United States securities and exchange commission logo August 3, 2022 Joseph Michael Redmond President and Chief Executive Officer Odyssey Health, Inc. |
|
| July 29, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on July 29, 2022. |
|
| July 29, 2022 |
Calculation of Registration Fees Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee (1) Common Stock, $0. |
|
| July 29, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 13, 2022 |
Exhibit 99.1 Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) - Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Asc |
|
| June 14, 2022 |
Exhibit 10.8 Amendment #2 to Promissory Note This AMENDMENT (this ?AMENDMENT?) is entered into by and between Company and Holder (each as defined below), effective as of June 3, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (?BORROWER?) and (?LENDER?) entered into that certain Promissory Note (the ?Note?) dated December 2021, as |
|
| June 14, 2022 |
Exhibit 10.5 Amendment to Promissory Note This AMENDMENT (this ?AMENDMENT?) is entered into by and between Company and Holder (each as defined below), effective as of April 20, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. Odyssey Group International, Inc. (?BORROWER?) and (?LENDER?) entered into that certain Promissory Note (the ?Note?) dated December , 2021 in |
|
| June 14, 2022 |
EX-10.4 5 odysseyex1004.htm REGISTRATION RIGHTS AGREEMENT Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 13, 2022, between Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” an |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File No. 00 |
|
| June 14, 2022 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 14, 2022 |
Exhibit 10.1 To subscribe for Common Stock and Warrants in the private offering of ODYSSEY HEALTH, INC. 1. Date and Fill in the number of shares of Common Stock, par value $0.001 per share of the Company (the ?Shares?) and associated warrant (the ?Warrants? and, collectively with the Shares, the ?Securities?) to purchase one-half of a share of Common Stock, at a combined purchase price of $0.35 pe |
|
| June 14, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of [], 2022, between Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subje |
|
| June 14, 2022 |
Exhibit 10.9 Amendment #2 to Convertible Promissory Note This AMENDMENT (this ?Amendment?) is entered into by and between Company and Holder (each as defined below), effective as of June 10, 2022 (the ?Effective Date?), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (?Company?) and LGH Investments, LLC (?Holder?) entered into that certain Convertible Promisso |
|
| May 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 6, 2022 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 6, 2022 |
EX-99.1 2 odyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug May 5, 2022 Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV |
|
| April 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 20, 2022 |
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board Exhibit 99.1 Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC:ODYY) (the ?Company? or ?Odyssey?), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy |
|
| April 20, 2022 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 14, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 ODYSSEY HEALTH, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 14, 2022 |
Exhibit 10.1 AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This AMENDMENT (this "Amendment") is entered into by and between Company and Holder (each as defined below), effective as of March 31, 2022 (the "Effective Date"), binding on the undersigned parties as of that date. RECITALS Odyssey Group International, Inc. ("Company") and Tysadco Partners, LLC ("Holder") entered into that certain Convertible |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0 |
|
| February 18, 2022 |
EX-10.1 2 odyex1001.htm AMENDMENT TO CONVERTIBLE PROMISSORY NOTE Exhibit 10.1 Amendment to Convertible Promissory Note This AMENDMENT (this “Amendment”) is entered into by and between Company and Holder (each as defined below), effective as of February 1, 2022 (the “Effective Date”), binding on the undersigned parties as of that date. RECITALS Odyssey Group Intl, Inc. (“Company”) and LGH Investmen |
|
| February 18, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorporation) |
|
| January 10, 2022 |
Exhibit 99.1 Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced that it has received a donation in the amount of $500,000 in partnership wi |
|
| December 30, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporation |
|
| December 27, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporation |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 21, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 333-250896 (Commission File Number) Nevada 47-1022125 (State or other jurisdi |
|
| December 27, 2021 |
EX-10.1 2 odyex1001.htm PROMISSORY NOTE Exhibit 10.1 PROMISSORY NOTE THIS PROMISSORY NOTE (the “Note”) is made as of the day of December 2021, by and between Odyssey Group International, Inc., Nevada corporation, (hereinafter known as “BORROWER”) and , an individual (hereinafter known as “LENDER”), whose address is . BORROWER and LENDER shall collectively be known herein as “the Parties”. In deter |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 00 |
|
| November 4, 2021 |
8-K 1 odyssey8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 333-250896 (Commission File Number) Nevada 47-102 |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 odyssey10k-073121.htm FORM 10-K FOR THE PERIOD 07-31-21 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 22, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 333-250896 (Commission File Number) Nevada 47-1022125 (State or other jurisdic |
|
| October 26, 2021 |
EX-10.1 2 odysseyex1001.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as October 22, 2021, is entered into by and between Odyssey Group Intl Inc., a Nevada corporation, (the “Company”), and Lincoln Park Capital, LLC (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in r |
|
| October 26, 2021 |
Warrant dated October 22, 2021 issued to Lincoln Park Capital, LLC. EX-10.2 3 odysseyex1002.htm WARRANT Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGI |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 18, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) 333-250896 (Commission File Number) Nevada 47-1022125 (State or o |
|
| October 26, 2021 |
EX-10.1 2 odysseyex1001.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as October 18, 2021, is entered into by and between Odyssey Group Intl Inc., a Nevada corporation, (the “Company”), and Tysadco Partners (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in reliance u |
|
| October 21, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as October 18, 2021, is entered into by and between Odyssey Group Intl Inc., a Nevada corporation, (the ?Company?), and Tysadco Partners (the ?Buyer?). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by |
|
| October 21, 2021 |
8-K 1 odyssey8k.htm FORM 8-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) 333-250896 (Commission File Number) Nevada 47- |
|
| October 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporation) |
|
| October 21, 2021 |
Warrant, dated October 18, 2021 issued to Tysadco Partners LLC. Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRAN |
|
| October 21, 2021 |
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device. |
|
| September 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporatio |
|
| September 24, 2021 |
Odyssey Group International Begins Enrolling Subjects for EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the |
|
| September 15, 2021 |
Submission of Matters to a Vote of Security Holders U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporatio |
|
| September 1, 2021 |
Odyssey Group International Approved to Start Human Trial to Treat Concussion EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Group International Approved to Start Human Trial to Treat Concussion Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced their approval to begin Phase 1 human clinical trials for drug candidate PRV-002 intended to treat concuss |
|
| September 1, 2021 |
EX-10.1 2 odysseyex1001.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 31, 2021August 29, 2021, is entered into by and between Odyssey Group Intl Inc., a Nevada corporation, (the “Company”), and Tysadco Partners (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreem |
|
| September 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporation |
|
| September 1, 2021 |
8-K 1 odysseyi8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 29, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 333-250896 (Commission File Number) Nevada |
|
| August 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other jurisdiction of incorpor |
|
| August 6, 2021 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| August 6, 2021 |
Exhibit 99.1 Odyssey Group International Completes IND-enabling Studies, Submits Investigator?s Brochure for Phase 1 Clinical Trial Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the successful completion of their Investigational New Drug (?IND?) enabli |
|
| July 26, 2021 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| July 6, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporation) (C |
|
| June 21, 2021 |
LGH Investments, LLC Settlement Agreement Exhibit 10.3 SETTLEMENT AGREEMENT THIS SETTLEMENT AGREEMENT (this ?Agreement?), dated March 5, 2021 (the ?Effective Date?), by and between Odyssey Group Intl, Inc., a Nevada corporation (the ?Company?) and LGH Investments, LLC (?LGH?). The Company and LGH are each respectively referred to herein as a ?Party? and collectively as ?the Parties.? WHEREAS, the Parties entered into that certain Securiti |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 odyssey043021.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] N-CEN For Period Ended: April 30, 2021 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q For the Transition Period Ended: |
|
| May 28, 2021 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 000-56196 (Commission File Number) Nevada 47-1022125 (State or other jurisdiction o |
|
| May 7, 2021 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| April 21, 2021 |
April 21, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Odyssey Group International, Inc. Request for Withdrawal of Registration Statement on Form S-3 Filed on March 17, 2021 File No.: 333-254402 Ladies and Gentlemen: On March 17, 2021, Odyssey Group International, Inc., a Nevada corporation (the “Company”), filed |
|
| April 7, 2021 |
Securities Purchase Agreement with LGH Investments, LLC. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of April 5, 2021, is entered into by and between Odyssey Group Intl Inc., a Nevada corporation, (the ?Company?), and LGH Investments, LLC, a Wyoming limited liability company (the ?Buyer?). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption |
|
| April 7, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 333-250896 47-1022125 (State or other jurisdiction of incorporation) (Co |
|
| March 17, 2021 |
S-3 1 odysseys3.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 17, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Odyssey Group International, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other jurisdiction of |
|
| March 17, 2021 |
Specimen Certificate representing shares of Common Stock Exhibit 4.1 |
|
| March 11, 2021 |
Form of Common Stock Subscription Agreement Exhibit 10.8 COMMON STOCK PURCHASE AGREEMENT THIS AGREEMENT is made and entered into this th day of 2021, by and between Odyssey Group International, a Nevada corporation, with its principle place of business at 2372 Morse Ave. Irvine CA 92614 (?Seller?) and with a principal address at (?Buyer?). WHEREAS, Seller is the record owner and holder of the capital stock of Odyssey Group International, In |
|
| March 11, 2021 |
Exhibit 10.4 ODYSSEY GROUP INTERNATIONAL, INC RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this ?Agreement?) is made and entered into between Odyssey Group International, Inc. (the ?Company?) and Christine Farrell (?Grantee?), effective as of January 1, 2021 (the ?Date of Grant?). This Agreement sets forth the terms and conditions associated with the Company?s |
|
| March 11, 2021 |
Exhibit 10.3 ODYSSEY GROUP INTERNATIONAL, INC RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this ?Agreement?) is made and entered into between Odyssey Group International, Inc. (the ?Company?) and Joseph Michael Redmond (?Grantee?), effective as of January 1, 2021 (the ?Date of Grant?). This Agreement sets forth the terms and conditions associated with the Compa |
|
| March 11, 2021 |
Form of Warrant to Purchase Shares Exhibit 10.9 WARRANT AGREEMENT THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR AN OPINION OF COUNSEL SATISFACTORY TO THE |
|
| March 11, 2021 |
10-Q 1 odyssey10q-013121.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition |
|
| March 11, 2021 |
Form of Private Placement Common Stock Purchase Warrant Agreement Exhibit 10.7 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRAN |
|
| March 11, 2021 |
Form of Private Placement Common Stock Purchase Agreement Exhibit 10.6 COMMON STOCK PURCHASE AGREEMENT THIS AGREEMENT is made and entered into this 5th day of March 2021, by and between Odyssey Group International, Inc. a Nevada corporation, with its principle place of business at 2372 Morse Ave, Irvine California 92614 (?Seller?) and the undersigned with a principal address set forth below. (?Buyer?). WHEREAS Seller is the record owner and holder of the |
|
| March 11, 2021 |
Form of Confidential Private Placement Memorandum Exhibit 10.5 Name: Copy No.: CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM For Accredited Investors Only Odyssey Group International, Inc. A Nevada Corporation CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM For Accredited Investors Only March 5, 2021 This Confidential Private Placement Memorandum is for the confidential use of the Offeree named on this cover page and may not be reproduced in whole or in pa |
|
| March 2, 2021 |
Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug EX-99.1 2 odysseyex9901.htm PRESS RELEASE Exhibit 99.1 Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021 IRVINE, CA March 2, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving |
|
| March 2, 2021 |
8-K 1 odyssey8k.htm CURRENT REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Nevada 000-56196 47-1022125 (State or other |
|
| January 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 odyssey8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2021 Date of Report (Date of earliest event reported) ODYSSEY GROUP INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 333-200785 (Commission File Number) Nevada |
